Skip to main content
TipRanks
Go Ultimate75% OFF

Werewolf Therapeutics (HOWL) Stock Price & Analysis

806 Followers

HOWL Stock Chart & Stats

$1.03-$0.02(-1.90%)
At close: 4:00 PM EST
$0.5$0.75$1Aug 24Sep 8Sep 21Oct 5Oct 19Nov 2Nov 16
Day’s Range
$0.98 - $1.15
52-Week Range
$0.27 - $1.20
Previous Close
$1.05
Volume
N/A
Average Volume (3M)
448.82K
Market Cap
$51.03M
Enterprise Value
$2.95M
Total Cash (Recent Filing)
$41.87M
Total Debt (Recent Filing)
$0
Price to Earnings (P/E)
―
Beta
1.42
Next Earnings
Mar 25, 2027 (Est.)
EPS Estimate
N/A
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Strong Gross Margins

An approximately 86% gross margin indicates attractive economics on recognized revenue and provides substantial room to fund operating investment if commercial or partnered revenue expands. This gross-profit profile is a durable strength, although it has not yet offset the company’s substantial research and development costs.

Clinical Validation

Clinical responses across multiple solid-tumor settings, together with increased T-cell activation and FDA alignment on the recommended Phase 2 dose, strengthen the platform’s development credibility. These data may support broader clinical advancement and partnering potential over the next several quarters.

Extended Funding Runway

The committed financing materially extends the projected cash runway and should allow the combined company to pursue major clinical and regulatory milestones without relying immediately on additional capital. Greater funding visibility supports continued program execution and reduces near-term financing pressure.

Bears Say

Persistent Unprofitability

Deep operating and net losses show that the current business does not yet convert its strong gross margin into sustainable earnings. Continued investment may be necessary before profitability, leaving results sensitive to clinical spending levels and making the path to durable self-funded operations uncertain.

Ongoing Cash Burn

Negative operating and free cash flow indicate that the company continues consuming cash to operate and advance its pipeline. The deterioration in free cash flow versus the prior comparable measure increases dependence on financing, transactions, or future partnering proceeds to sustain development.

Reduced Equity Base

The sharp multi-year reduction in equity reflects the cumulative effect of sustained losses and weakens balance-sheet durability. Even with zero total debt in the latest period, a much smaller equity base provides less financial resilience and leaves less capacity to absorb setbacks or fund programs internally.

Werewolf Therapeutics News

HOWL FAQ

What was Werewolf Therapeutics’s price range in the past 12 months?
Werewolf Therapeutics lowest stock price was $0.27 and its highest was $1.20 in the past 12 months.
What is Werewolf Therapeutics’s market cap?
Werewolf Therapeutics’s market cap is $51.03M.
When is Werewolf Therapeutics’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Werewolf Therapeutics’s earnings last quarter?
Werewolf Therapeutics released its earnings results on Nov 05, 2026. The company reported -$0.203 earnings per share for the quarter, beating the consensus estimate of -$0.22 by $0.017.
Is Werewolf Therapeutics overvalued?
Not enough analysts have published a price target to calculate whether the price is overvalued.
Does Werewolf Therapeutics pay dividends?
Werewolf Therapeutics does not currently pay dividends.
What is Werewolf Therapeutics’s EPS estimate?
Werewolf Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Werewolf Therapeutics have?
Werewolf Therapeutics has 48,599,068 shares outstanding.
What happened to Werewolf Therapeutics’s price movement after its last earnings report?
Werewolf Therapeutics reported an EPS of -$0.203 in its last earnings report, beating expectations of -$0.22. Following the earnings report the stock price went down -6.422%.
Which hedge fund is a major shareholder of Werewolf Therapeutics?
Hedge funds hold Werewolf Therapeutics shares: the largest hedge-fund position in Werewolf Therapeutics is 72,326,851 shares, and hedge funds decreased their holdings by 4.3M shares last quarter.
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology